Studying brain blood pressure control in Parkinson disease with low blood pressure on standing
Compares brain responses to lower body suction in Parkinson disease with or without orthostatic hypotension.
Plain-language title generated from the registry record
Registry title: Deciphering the Mechanisms of Central BP Regulation in Patients With PD Associated With Orthostatic Hypotension
Key facts
- Where
- Lausanne, SwitzerlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07139756, who can take part
Where in Switzerland
- Centre Hospitalier Universitaire VaudoisLausanne, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire Vaudois
- Trial code
- NCT07139756
- Record updated
- 24 August 2025
- Original description
Phase 1 objective: test the feasibility of using a 3Tesla MRI scanner instead of a 7Tesla MRI scanner to measure brainstem responses to LBNP in healthy participants.Read full original descriptionShow less
Deciphering the Mechanisms of Central Blood Pressure Regulation in Patients With Parkinson Disease Associated With Orthostatic Hypotension: A 2-phase Observational Study With Healthy Participants and Patients With Parkinson's Disease
Phase 1 objective: test the feasibility of using a 3Tesla MRI scanner instead of a 7Tesla MRI scanner to measure brainstem responses to LBNP in healthy participants.
Phase 2 primary objective: compare the brainstem responses to LBNP in patients with PD associated with OH to PD patients without OH using BOLD fMRI
Inclusion: Signed informed consent; Age ≥ 18 years and <75 years; Normal office blood pressure (<140/90 mmHg); For women of childbearing potential: using or willing to use during the study a reliable contraception method compatible with MRI; Signed informed consent; Fulfilling Movement Disorder Society clinical criteria for "clinically established PD"; Age ≥18 years and <75 years; PD treated by dopamine replacement therapy (DRT); Willing and able to comply with the visit schedule and study procedures; Autonomous in daily life; Schellong test showing OH (drop of Systolic BP >20 mmHg or Diastolic BP >10 mmHg)(for study group with OH) or no OH (for studygroup without OH); For women of childbearing potential: using or willing to use during the study a reliable contraception method compatible with MRI.
Exclusion: Any medication (acute or chronic prescription) except oral contraception; Concomitant participation in a clinical trial; Blood donation in the 60 previous days; Blood donation in the previous 6 months; Chronic or acute illness; Allergy to components of contrast agent Sonovue®; Dementia; Type 2 diabetes; Stroke or myocardial infarction in the past 6 months; eGFR < 45 ml/min/1.73 ml/min/m2 by CKD-EPI equation; Schellong test showing OH (drop of Systolic BP >20 mmHg or Diastolic BP >10 mmHg); Pregnant or lactating women; Refusal to be informed of incidental findings; Clinical significant abnormal blood test as assessed by the investigator; Contra-indications for MRI; Unable to follow study procedures; Having a hierarchical relationship with the investigator or being family of the investigator; Phase 2:; Unable to give an informed consent; BP > 180/110 mmHg on 24-hour ambulatory blood pressure monitoring; having contra-indications for MRI; Pregnant or lactating women; Refusal to be informed of incidental findings; Living in an institution; Active oncology treatment; Having a hierarchical relationship with the investigator or being family of the investigator.
Phase 1:.